Radiosurgery systems maker,
) announced that France-based Centre Oscar Lambret is the first
to use its latest TomoHDA System to treat its patient. The
advanced fully-integrated radiation therapy system combines
TomoTherapy Hi-Art and Tomo HD technologies to treat cancer
ACCURAY INC (ARAY): Free Stock Analysis
NATUS MEDICAL (BABY): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
INTUITIVE SURG (ISRG): Free Stock Analysis
To read this article on Zacks.com click here.
Accuray had acquired Wis.-based radiation system maker
TomoTherapy in Jun 2011. TomoTherapy markets advanced radiation
therapies for treating multiple cancer types. The TomoTherapy
Systems are advanced radiation therapy systems, which provide
precise and safe radiation therapy by combining CT imaging and
radiation treatment delivery in a single device, thereby lowering
Accuray had achieved a major milestone with the launch of the new
TomoTherapy H Series, featuring the TomoHDA System, at the ASTRO
meeting in Oct 2012. This unique series is considered to be the
near-term growth driver for the company.
Prior to the ASTRO meeting, the TomoTherapy System occupied a
niche position in the market, as it was considered as a specialty
device used to deliver IMRT (intensity-modulated radiation
therapy) for complex cases. The launch of the TomoTherapy H
Series, which provide treatments that cover the entire spectrum
of radiation therapy patients, positions the product line in the
Features such as the VoLO Technology and the TomoEDGE Dynamics
Jaws technology are available with the TomoHDA system, which
makes it the gold standard for image-guided IMRT. VoLO provides
real-time efficiency for treatment planning and dose calculation.
The advanced TomoEDGE technology is capable of providing precise
dosage of radiation in lesser time. This allows for more
treatments per day without compromising on clinical
efficiency. Moreover, the 3D imaging technology allows
doctors to deliver radiation to only the tumor site, without
harming the surrounding healthy tissues.
Accuray's product order momentum, reflecting healthy product
adoption of new products encourages us. Earlier, the company had
sold its latest TomoTherapy devices to Germany-based Heidelberg
University Hospital, thereby enhancing growth in Europe.
However, a lot needs to be done to bring the company back on
track. We remain concerned over Accuray's declining top and
bottom line along with reduced full-year guidance. Management
needs to improve its higher-margin product revenues and
aggressively remediate its structural issues for new offerings to
fully contribute to total sales.
The stock currently carries a Zacks Rank #3 (Hold). While we
remain on the sidelines regarding Accuray, medical instrument
companies such as
) are worth considering. While CYBX and BABY carry a Zacks Rank
#1 (Strong Buy), ISRG carries a Zacks Rank #2 (Buy).